Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807741 · ClinicalTrials.gov registry record · Phase 2
Asenapine for Bipolar Depression
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT01807741 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 51 participants.
The verdict
NCT01807741, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks. We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Asenapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807741
The ClinicalTrials.gov registry entry for NCT01807741 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01807741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807741 about?
NCT01807741 is a clinical study titled "Asenapine for Bipolar Depression". The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks. We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.
What is the current status of trial NCT01807741?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2013-09. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01807741?
The interventions under investigation include: Placebo (DRUG), Asenapine (DRUG).
Who is sponsoring clinical trial NCT01807741?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.